Mid-Morning Market Update: Markets Open Lower; US Economy Adds 390,000 Jobs In May
U.S. stocks traded lower this morning, with the Dow Jones dropping around 150 points on Friday.
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month, bringing the total for the year to 15. This compares to the 24 NMEs the Food and Drug Administration approved by May 2021.
Amylyx Pharmaceuticals Announces Presentation Of New Analysis Of Centaur Trial Results At The European Network To Cure ALS 2022 Meeting
Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the
Benzinga’s Top Ratings Upgrades, Downgrades For May 25, 2022
Upgrades
Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of $5.92. Molecular Partners closed at $6.88 at the end of the last trading period.
Amylyx Pharmaceuticals Announces Publication Of Data Showing Randomization To AMX0035 Prolonged Tracheostomy/Ventilation-Free Survival And Reduced Occurrence Of First Hospitalization
Adding to previously reported overall functional and survival benefit data for AMX0035, these findings support effect of AMX0035 on disease progression in ALS
Randomization to AMX0035 resulted in a lower
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that moved stocks during the week.
SVB Leerink Maintains Outperform on Amylyx Pharmaceuticals, Lowers Price Target to $31
SVB Leerink analyst Marc Goodman maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and lowers the price target from $50 to $31.